

**Supplementary Table II. Stratified relative risk of non-Hodgkin lymphoma (NHL) after first primary solid cancer according to initial radiotherapy treatment by age**

First Primary Cancer	Radiotherapy		No Radiotherapy		RR* and 95% CI	Ptrend
	Obs	SIR	Obs	SIR		
<b>All solid cancers</b>						
<40	81	2.55	263	3.09	1.02 (0.68-1.52)	>0.50
40-54	249	1.31	532	1.11	1.28 (1.08-1.52)	
55-64	421	1.03	1,041	0.93	1.12 (1.00-1.26)	
65-74	733	1.00	1,468	0.90	1.11 (1.01-1.21)	
75+	258	1.03	544	0.90	1.12 (0.96-1.31)	
<b>All standard radiotherapy treated solid cancers<sup>†</sup></b>						
<40	32	1.21	58	1.31	0.92 (0.59-1.44)	>0.50
40-54	187	1.09	234	0.85	1.33 (1.09-1.62)	
55-64	386	1.03	648	0.92	1.11 (0.98-1.27)	
65-74	693	1.00	941	0.89	1.11 (1.00-1.23)	
75+	247	1.04	310	0.85	1.20 (1.01-1.43)	
<b>Oral cavity &amp; pharynx</b>						
<55	16	1.13	22	1.42	1.21 (0.57-2.56)	0.405
55-64	28	1.39	23	0.94	1.10 (0.57-2.15)	
65+	29	1.18	47	1.24	0.63 (0.37-1.09)	
<b>Larynx</b>						
<55	8	0.91	5	1.55	0.62 (0.20-1.90)	>0.50
55-64	19	0.90	10	1.37	0.85 (0.37-1.96)	
65+	32	1.15	8	0.99	1.08 (0.49-2.35)	
<b>Thyroid</b>						
<55	22	1.40	22	0.87	1.41 (0.75-2.65)	>0.50
55-64	14	1.69	13	0.97	1.46 (0.66-3.21)	
65+	9	1.02	12	0.98	0.92 (0.38-2.22)	
<b>Lung &amp; bronchus (NSC)</b>						
<55	11	1.77	12	0.75	2.92 (0.99-8.59)	>0.50
55-64	22	1.46	42	0.96	1.65 (0.91-3.01)	
65+	29	0.92	81	0.88	1.32 (0.81-2.13)	
<b>Female breast</b>						

<55	91	0.96	113	0.81	1.17 (0.88-1.55)	0.318
55-64	116	0.93	187	0.95	1.00 (0.79-1.26)	
65-74	112	0.76	205	0.85	0.89 (0.70-1.12)	
75+	36	0.73	81	0.90	0.79 (0.53-1.17)	
<b>Cervix uteri</b>						
<55	12	1.39	20	1.23	1.58 (0.72-3.46)	0.318
55+	18	1.20	13	1.26	0.59 (0.26-1.36)	
<b>Endometrium</b>						
<55	11	0.99	33	1.09	0.77 (0.37-1.60)	0.187
55-64	32	0.98	51	0.77	1.22 (0.77-1.94)	
65+	50	1.03	60	0.71	1.49 (1.01-2.18)	
<b>Prostate</b>						
<55	17	1.24	44	0.99	1.36 (0.77-2.39)	>0.50
55-64	124	1.00	278	0.92	1.11 (0.89-1.38)	
65-74	425	1.06	518	0.91	1.15 (1.01-1.31)	
75+	162	1.12	151	0.79	1.44 (1.14-1.82)	
<b>Testis</b>						
<40	10	1.25	6	0.63	2.01 (0.64-6.30)	>0.50
40+	12	1.27	4	0.73	1.18 (0.38-3.65)	
<b>Rectum &amp; rectosigmoid junction</b>						
<55	12	1.27	13	0.77	0.97 (0.29-3.26)	0.125
55-64	19	0.87	36	0.76	0.57 (0.27-1.18)	
65+	47	1.28	81	0.88	1.86 (1.18-2.94)	

Abbreviations: NSC, non-small cell; Obs, observed; SIR, standardized incidence ratio; RR, relative risk; CI, confidence interval

\*Poisson regression modeling used to estimate RR of NHL comparing radiotherapy treatment groups for first primary cancer stratified by sex,

age, stage, and chemotherapy.

†Includes oral cavity & pharynx, rectosigmoid junction & rectum, larynx, lung & bronchus (NSC), female breast, cervix uteri, endometrial, prostate, testis, and thyroid cancers.